Drug Profile
Tebentafusp - Immunocore
Alternative Names: IMC-gp100; ImmTAC-gp100; KIMMTRAK; Monoclonal T cell receptor anti-CD3 scFv fusion protein (IMCgp100); Tebentafusp-tebnLatest Information Update: 11 Mar 2024
Price :
$50
*
At a glance
- Originator Immunocore
- Developer Immunocore; Natera; University of Oxford
- Class Antineoplastics; Immunoglobulin fragments; Immunotherapies; Recombinant fusion proteins
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Uveal melanoma
- Phase II/III Malignant melanoma
Most Recent Events
- 11 Mar 2024 Launched for Uveal melanoma (First-line therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease) in Australia (IV) (Prior to February 2024)
- 28 Feb 2024 Launched for Uveal melanoma (First-line therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease) in Canada (IV) (Prior to February 2024)
- 07 Nov 2023 Immunocore enters into a clinical trial collaboration agreement with The European Organisation for Research and Treatment of Cancer (EORTC) to investigate tebentafusp adjuvant treatment for uveal melanoma